SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small-molecule drugs to activate the immune system, today announced the selection of FLX475 as its first immuno-oncology clinical candidate for the treatment of cancer. FLX475 is a best-in-class, oral, small molecule antagonist of CCR4. By blocking CCR4, a receptor protein that plays a role in the recruitment and accumulation of regulatory T (Treg) cells in the tumor environment, FLX475 has the potential to provide a new mechanism to treat cancer. FLX Bio expects to begin clinical trials of FLX475 in late 2017.
“Tumors surround themselves with a barrier of regulatory T cells, preventing a normal immune response,” stated Alexander Rudensky, Chairman of FLX Bio’s Scientific Advisory Board and Chair of the Immunology Program at the Sloan Kettering Institute, Director of the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center and Member, National Academy of Sciences. “CCR4 represents a key pathway by which tumors recruit regulatory T cells to suppress tumor immunity. By blocking this pathway with a CCR4 antagonist, it may be possible to prevent regulatory T cell recruitment to the tumor site, reduce the number of regulatory T cells in the tumor and importantly, enable immune activation and tumor killing.”
In April 2017, FLX Bio researchers presented preclinical efficacy data on internally-generated CCR4 antagonists at the American Association of Cancer Research Conference. The data demonstrated that FLX Bio’s CCR4 antagonists are potent and selective, reduce regulatory T cells selectively at the tumor site and reverse tumor growth in mouse models particularly when combined with other immuno-oncology agents.
Brian R. Wong, M.D., Ph.D., CEO of FLX Bio commented, “Based upon compelling preclinical data, we look forward to advancing FLX745 into clinical trials later this year. FLX475 was generated using FLX Bio’s integrated discovery engine, which the company is leveraging to build a pipeline of small molecule compounds targeting regulatory T cells or tumor myeloid cells, both of which work upstream of checkpoint inhibitors and prevent tumor immunity.”
Appointment of Scott J. Antonia, M.D., Ph.D., to Scientific Advisory Board
FLX Bio also announced the appointment of Scott J. Antonia, M.D., Ph.D., Chair of the department of thoracic surgery for Moffitt Cancer Center, to its scientific advisory board (SAB).
Dr. Antonia joins Philip Greenberg, M.D., David Goeddel, Ph.D., Drew Pardoll, M.D., Ph.D., Antoni Ribas, M.D., Ph.D., Alexander Rudensky, Ph.D. and Robert Zamboni, Ph.D., bringing the total FLX Bio SAB to seven key opinion leaders in immunotherapy.
“Scott is a highly-respected and experienced investigator and clinician in the immuno-oncology field, and we are thrilled to add his expertise to our robust scientific advisory board,” Dr. Wong continued. “With FLX475 entering the clinic later this year, we look forward to applying Scott’s deep knowledge as we select specific cancer targets for our clinical candidates.”
Dr. Antonia serves as the chair of the thoracic oncology department at the H. Lee Moffitt Cancer Center and Research Institute as well as professor of Oncologic Sciences at the University of South Florida College of Medicine. His expertise lies in treating cancer patients through immunotherapeutic strategies to thwart the immunosuppressive mechanisms used by tumors to evade T cell-mediated rejection. He has designed and conducted numerous cutting-edge studies with novel immunotherapeutic agents. Dr. Antonia has received numerous awards including Moffitt Physician of the Year, Moffitt Mentor of the Year and the W. Jackson Pledger Researcher of the Year and was inducted into the National Academy of Inventors in 2015. He received his M.D. and Ph.D. in Immunology from the University of Connecticut Health Center in Farmington, Connecticut. He completed an internal medicine residency and pursued additional medical oncology and immunobiology training at Yale University School of Medicine. He is the author of several peer-reviewed publications and an inventor on two patents.
About C-C Chemokine Receptor 4 (CCR4)
CCR4 is a receptor protein expressed on regulatory T cells. While regulatory T cells help prevent autoimmune diseases and control inflammation in a healthy body, cancer cells can co-opt this protective feature by recruiting large numbers of regulatory T cells to a tumor site (tumor microenvironment). Within the tumor microenvironment, regulatory T cells prevent the body from mounting an immune response to eliminate the cancer cells, allowing tumor growth to proceed unchecked. To recruit regulatory T cells, cells in tumors send out chemical signals (CCL17 and CCL22) which bind to CCR4. FLX475 inhibits CCR4 to prevent the unwanted migration of regulatory T cells to the site of a tumor.
About FLX475
FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 antibodies as well as immune agonists such as anti-4-1BB. In addition, FLX475 has the potential to enhance cell-based immunotherapies such as CAR-T and cancer vaccines. Unlike antibodies to CCR4, FLX475 selectively blocks the recruitment of regulatory T cells to the tumor site, and does not deplete regulatory T cells in healthy tissue such as blood, spleen or skin. FLX Bio intends to initiate clinical trials of FLX475 alone and in combination with checkpoint inhibitors in late 2017.
About FLX Bio
FLX Bio, Inc. is a cancer immunotherapy company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, FLX Bio’s small molecule compounds specifically target proteins and pathways that selectively inhibit regulatory T cells and myeloid cells within the tumor microenvironment. Its lead candidate, a best-in-class CCR4 inhibitor, has the potential to be used alone or in combination with checkpoint inhibitors to treat a variety of cancers, and is expected to enter the clinic in 2017.
Located in South San Francisco, Calif., and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG), Topspin Partners and Celgene, FLX Bio has assembled a leadership team and advisory group with a proven track record of success and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.
